For people living with a rare, autoimmune, neuromuscular condition like MG (Myasthenia Gravis), this is not a hypothetical question. Fatigue, muscle weakness and fluctuating symptoms can turn everyday activities into constant adaptations.
Mobility is not only about walking from one place to another. It is also about planning ahead, managing energy, staying independent, continuing to work, maintaining social connections, and navigating uncertainty day after day.
You do not have to face these challenges alone.
That is why we are launching Dare to Move, an initiative designed to create a space for connection, support, and shared experiences around mobility and rare autoimmune diseases.
Living with MG means facing daily questions: can I still travel the same way? How do I balance activity and rest? Will people understand what I am going through? What happens when symptoms suddenly change?
Dare to Move brings together people across Europe to explore mobility in all its dimensions: from diagnosis and access to care, to daily life, social participation, rights, cross border realities, and future outlook.
It aims to make visible what mobility truly means for people living with MG: not only the ability to move, but the ability to live independently and stay connected.
From June 2026 onwards, the initiative will unfold through public awareness activations, patient stories, and discussions culminating in European roundtables in Brussels this September.
For people living with MG, mobility is far from guaranteed. Its a rare autoimmune disease that causes muscle weakness and fatigue. The impact on daily life is profound (1)
49%
struggle with tiredness.
30%
have problems with performing everyday activities.
22%
have feelings of anxiety and depression.
Real testimonials, real words. Voices from the community.
- Jihane Sayadi-Herniere, a mother and manager living with Myasthenia Gravis
MED EU UNB 2600097 Date of preparation: May 2026
REFERENCES :
1. Dewilde S, Philips G, Paci S, et al, Patient reported burden of myasthenia gravis: baseline results of the international prospective, observational, longitudinal real world digital study MyRealWorld MGBMJ Open 2023;13:e066445. doi: 10.1136/bmjopen 2022 066445